We therefore hypothesize that the frequency of CD57+ CD4+ T cells in blood represents a novel cellular biomarker of recent or active IFN responses in patients with systemic autoimmunity, which could have informative clinical application for the monitoring of disease activity in SLE. This evidence concerns the gene CD4 and systemic lupus erythematosus.